Gannex, a wholly owned company of Ascletis Pharma Inc (HKEX: 1672), announced on Wednesday that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application and initiation of global development of ASC41 oral tablet, a liver-targeted prodrug.
The product is a selective thyroid hormone receptor beta (THR-beta) agonist.
The approval was based on efficacy and safety data from the phase one randomised, double-blind, placebo controlled single- and multiple-ascending dose study in 65 patients completed in China and commercially ready oral tablet formulation developed with in-house proprietary technology.
The approval allows the firm to commence clinical trials in the United States.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval